Hansoh Pharmaceutical Group Company Limited (HNSPF)

Market Cap	32.71B
Revenue (ttm)	1.84B
Net Income (ttm)	667.42M
Shares Out	n/a
EPS (ttm)	0.11
PE Ratio	49.01
Forward PE	44.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	1,824
Open	5.00
Previous Close	4.51
Day's Range	5.00 - 5.00
52-Week Range	1.95 - 5.58
Beta	0.61
RSI	65.07
Earnings Date	Nov 17, 2025

About HNSPF

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 8,989
• Stock Exchange: OTCMKTS
• Ticker Symbol: HNSPF

Financial Performance

In 2024, HNSPF's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY